Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting

Fig. 2

Event-Free Survival and Overall Survival in the Per Protocol set (PPS) and in the modified Full Analysis set (mFAS). A EFS by study arm in the PPS. B OS by study arm in the PPS. C EFS by tpCR status in the PPS. D EFS by bpCR status in the PPS. E Event free survival in the mFAS. F Overall survival in the mFAS. bpCR, breast pathologic complete response; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; PPS, per protocol set; OS, overall survival; pCR, pathologic complete response; tpCR, total pathologic complete response

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us